Compare Cytokinetics Inc (CYTK) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| CYTK | IEI | |
|---|---|---|
Market Cap | $8.62B | $16.72B |
Volume | 2,594,626 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $120.72 |
52-Week Low | $54.76 | $113.17 |
Typical Hold Time | 19 Days | 43 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
IEI trades at $113.57 with minimal daily movement (+0.17%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling downward pressure, though oscillators suggest neutral momentum. Recent dividend payments of $0.37-0.38 per share demonstrate consistent shareholder returns. The stock faces headwinds from rising Treasury yields and bond market volatility, which could impact investor appetite for equities.
Outlook remains cautious as higher interest rates and bond market turbulence create challenging conditions. The bearish technical signals and neutral fundamental metrics suggest limited near-term upside potential. Key risks include continued bond market volatility and macroeconomic pressures, though consistent dividend payments provide some defensive characteristics for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
